Identifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic Macular Edema

Rajya L. Gurung 1,*, Liesel M. FitzGerald 1Ω, Ebony Liu 2, Bennet J. McComish 1, Georgia Kaidonis 2, Bronwyn Ridge 2, Alex W. Hewitt 1,3Ω, Brendan J. Vote 3, Nitin Verma 3, Jamie E. Craig 2 and Kathryn P. Burdon 1,*

Abstract: Intraocular anti-vascular endothelial growth factor (VEGF) therapies are the front-line treatment for diabetic macular edema (DME); however, treatment response varies widely. This study aimed to identify genetic determinants associated with anti-VEGF treatment response in DME. We performed a genome-wide association study on 220 Australian patients with DME treated with anti-VEGF therapy, genotyped on the Illumina Global Screening Array, and imputed to the Haplotype Reference Consortium panel. The primary outcome measures were changes in central macular thickness (CMT in microns) and best-corrected visual acuity (BCVA in ETDRS letters) after 12 months. Association between single nucleotide polymorphism (SNP) genotypes and DME outcomes were evaluated by linear regression, adjusting for the first three principal components, age, baseline CMT/BCVA, duration of diabetic retinopathy, and HbA1c. Two loci reached genome-wide significance (p < 5 × 10⁻⁸) for association with increased CMT: a single SNP on chromosome 6 near CASC15 (rs78466540, p = 1.16 × 10⁻⁹) and a locus on chromosome 12 near RP11-116D17.1 (top SNP rs11614480, p = 2.69 × 10⁻⁸). Four loci were significantly associated with reduction in BCVA: two loci on chromosome 11, downstream of NTM (top SNP rs148980760, p = 5.30 × 10⁻⁸) and intronic in RP11-744N12.3 (top SNP rs57801753, p = 1.71 × 10⁻⁸); one near PGAM1P1 on chromosome 5 (rs187876551, p = 1.52 × 10⁻⁸); and one near TBC1D32 on chromosome 6 (rs118074968, p = 4.94 × 10⁻⁸). In silico investigations of each locus identified multiple expression quantitative trait loci and potentially relevant candidate genes warranting further analysis. Thus, we identified multiple genetic loci predicting treatment outcomes for anti-VEGF therapies in DME. This work may potentially lead to managing DME using personalized treatment approaches.

Keywords: anti-vascular endothelial growth factor; diabetic macular edema; genome-wide association

1. Introduction

Diabetic macular edema (DME) is the most common cause of visual impairment in patients with diabetes and can affect patients with either Type 1 (T1) or Type 2 (T2) diabetes mellitus (DM). It is the leading cause of central vision loss in the working-age population with a prevalence of 1.4–12.8% in patients with diabetes [1]. Although the exact pathogenesis of DME remains elusive, there is strong evidence that it develops due to complex interactions between environmental and genetic factors [2,3]. It is characterized by the accumulation of fluid, lipids, and/or hemorrhages in the macula (the part of the
retina responsible for central vision) due to a breakdown of the blood–retinal barrier [4]. Angiogenic factors, such as vascular endothelial growth factor (VEGF), and inflammatory mediators have been postulated to be involved in the development of DME [5]. Since the advent of the first intravitreal anti-VEGF therapy in 2005 [6], the development of newer agents targeting the VEGF/VEGF-receptor has improved treatment outcomes for DME patients [7,8]. However, one-third of patients have an insufficient response to these currently available therapies [9,10]. A possible and significant consequence of an insufficient response is that the patient may suffer from ongoing macular injury at a molecular level, thereby leading to irreversible vision loss [11]. Several randomized control trials (RCTs) and clinic-based studies have attempted to identify ocular and systemic predictors of response to anti-VEGF treatment but there has been little research into the potential role of genetics [12,13]. There are only a few studies that have specifically aimed to identify genetic variants that distinguish between DME patients that do respond (“responders”) and do not respond (“non-responders”) to anti-VEGF injections [14–19]. Most, if not all, of these studies are candidate gene studies, with a small sample size, short follow-up period, and poorly defined response criteria. Therefore, we undertook a genome-wide association pilot study (GWAS) to explore genetic determinants of anti-VEGF treatment response in patients with DME.

2. Results

2.1. Cohort Characteristics

A total of 248 diabetic (T1 + T2) patients receiving anti-VEGF injections were identified with complete clinical data. Of these, genome-wide genotyping data were available for 234 individuals. After quality control (QC), 220 individuals with data for 2,581,674 autosomal SNPs were available for analysis. The details of the individual level and single nucleotide polymorphism (SNP) level QC are provided in the Materials and Methods section and Supplementary Materials: Supplement: Table S1. For these 220 patients, the mean change in central macular thickness (CMT) was −55.17 microns and the mean change in best-corrected visual acuity (BCVA) was 3.41 Early Treatment Diabetic Retinopathy Study letters (ETDRS letters) following 12 months of anti-VEGF treatment, indicating significant improvements in vision and macular thickness following treatment (p < 0.05 for both measures). Demographic information and clinical parameters of the study cohort are described in Table 1.

Table 1. Overall baseline and clinical characteristics.

| Variable                      | N = 220 |
|-------------------------------|---------|
| **Patient related**           |         |
| Age (years)                   | 66.35 (12.16) |
| Gender: Male, N (%)           | 151 (68.6) |
| BMI (kg/m²)                   | 33.76 (8.00) |
| DM: T2, N (%)                 | 181 (82.3) |
| DM duration (years)           | 22.74 (10.15) |
| HbA1c (mg/dl)                 | 8.38 (1.63) |
| HTN: Yes, N (%)               | 188 (85.5) |
| Nephropathy: Yes, N (%)       | 120 (54.5) |
| Hyperlipidemia: Yes, N (%)    | 198 (90) |
| Smoker: Yes, N (%)            | 111 (50.5) |

**Eye related**
Table 1. Cont.

| Variable                   | N = 220                                                                 |
|----------------------------|-------------------------------------------------------------------------|
| Baseline CMT (microns)     | 380.57 (104.08)                                                        |
| Final CMT (microns)        | 325.40 (75.38)                                                         |
| Change in CMT (microns)    | −55.17 (99.16) *                                                       |
| Laterality: RE, N (%)      | 113 (51.4)                                                             |
| Lens status: Phakic, N (%) | 141 (64.1)                                                             |
| DR duration (years)        | 7.95 (4.30)                                                            |
| DR severity N (%)          |                                                                       |
| Mild DR                    | 45 (20.5)                                                              |
| Moderate DR                | 67 (30.5)                                                              |
| Severe DR                  | 35 (15.9)                                                              |
| PDR                        | 72 (32.7)                                                              |
| Injection number           | 8.02 (3.07)                                                            |
| Injection type: N (%)      |                                                                       |
| Bevacizumab                | 126 (57.3)                                                             |
| Aflibercept                | 25 (11.4)                                                              |
| Ranibizumab                | 37 (16.8)                                                              |
| Mixed                      | 32 (14.5)                                                              |

Abbreviations: BCVA = best corrected visual acuity; BMI = body mass index; CMT = central macular thickness; DM = diabetes mellitus; DR = diabetic retinopathy; ETDRS = early treatment diabetic retinopathy study; HTN = hypertension; PDR = proliferative diabetic retinopathy; PRP = pan-retinal photocoagulation; RE = right eye. Data are presented as means (SD) for continuous variables and number, percentage (%) for categorical variables. * p < 0.05 for comparison of pre and post-treatment measures.

2.2. Association Analysis

2.2.1. Genome-Wide Significant Loci

Six SNPs at two loci showed genome-wide significant evidence for association with change in CMT, $p < 5 \times 10^{-8}$ (Figure 1A; Table 2). These included a single SNP, rs78466540, near cancer susceptibility candidate 15 (CASC15) gene on chromosome 6 (Supplementary Materials: Supplement: Figure S4A) and five SNPs, rs11614480 (lead SNP), rs11615848, rs11614887, rs11615870, rs11615833, in linkage disequilibrium (LD) near RP11-116D17.1 on chromosome 12 (Supplementary Materials: Supplement: Figure S4B). The details of all SNPs at each significant or suggestive locus are given in Supplementary Materials: SNP.xlsx (Sheet-1) and the corresponding Quantile–Quantile (Q–Q) plot in Supplementary Materials: Supplement: Figure S3A.

Four loci reached genome-wide significance for association with change in BCVA (Figure 1B, Table 2). The most significant locus was represented by two SNPs on chromosome 11, rs148980760 (lead SNP) and rs117744949 near the Neurotrimin (NTM) gene. A second locus on chromosome 11, rs57801753 in the RP11-744N12.3 gene, a single SNP on chromosome 5, rs187876551 near Phosphoglycerate Mutase 1 Pseudogene 1 (PGAM1P1), and a loci on chromosome 6, rs118074968 near the TBC1 Domain Family Member 32 (TBC1D32) also reached significance. Details of all SNPs are given in Supplementary Materials: SNP.xlsx (Sheet-2) and the corresponding Q–Q plot in Supplementary Materials: Supplement: Figure S3B and the regional plots as shown in Supplementary Materials: Supplement: Figure S5.
**Figure 1.** Association analyses for treatment response to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular edema (DME). The x-axis represents chromosomal position of each SNP, and the y-axis shows the -log10 (p-value) for association with (A): Change in central macular thickness (CMT) over 12 months of treatment and (B): Change in best-corrected visual acuity (BCVA) over 12 months. Red and blue horizontal lines correspond to the thresholds for genome-wide significant (\(p \leq 5 \times 10^{-8}\)) and suggestive association (\(p \leq 5 \times 10^{-7}\)), respectively.

**Table 2.** Genome-wide significant associations.

| Locus * | Chr | Position † | Lead SNP | Ref | Alt | AAF | Beta ‡ | p Value |
|---------|-----|------------|----------|-----|-----|-----|--------|---------|
| **Change in CMT (microns)** | | | | | | | | |
| CASC15 | 6 | 21755718 | rs78466540 | A | G | 0.03 | 115.80 | 1.16 × 10⁻⁰⁹ |
| **RP11-116D17.1** | 11 | 115772072 | rs11614480 | T | C | 0.07 | 71.08 | 2.69 × 10⁻⁰⁸ |
| | 12 | 115772088 | rs11615848 | G | T | 0.07 | 71.08 | 2.69 × 10⁻⁰⁸ |
| | 12 | 115772313 | rs11614887 | T | C | 0.07 | 71.02 | 2.73 × 10⁻⁰⁸ |
| | 12 | 115772214 | rs11615870 | G | T | 0.07 | 71.02 | 2.73 × 10⁻⁰⁸ |
| | 12 | 115772032 | rs11615833 | G | A | 0.07 | 70.84 | 4.04 × 10⁻⁰⁸ |
| **Change in BCVA (ETDRS letters)** | | | | | | | | |
| NTM | 11 | 132228056 | rs149890760 | A | C | 0.03 | −17.98 | 5.30 × 10⁻⁰⁹ |
| | 11 | 132237087 | rs117744949 | G | A | 0.03 | −17.50 | 6.57 × 10⁻⁰⁹ |
| PGAM1P1 | 5 | 57535905 | rs187867651 | G | A | 0.02 | −21.80 | 1.52 × 10⁻⁰⁸ |
| **RP11-744N12.3** | 11 | 128524088 | rs57801753 | T | C | 0.02 | −20.19 | 1.71 × 10⁻⁰⁸ |
| **TBC1D32** | 6 | 121280029 | rs118074968 | A | G | 0.03 | −16.40 | 4.94 × 10⁻⁰⁸ |

Abbreviations: Alt = alternate allele; AAF = alternate allele frequency; BCVA = best corrected visual acuity; CASC15 = cancer susceptibility candidate 15; Chr = chromosome; CMT = central macular thickness; ETDRS = early treatment diabetic retinopathy study; NTM = Neurotrimin; PGAM1P1 = Phosphoglycerate Mutase 1 Pseudogene 1; Ref = reference allele; SNP = single nucleotide polymorphism; TBC1D32 = TBC1 Domain Family Member 32. * Locus assigned to gene within or nearest to the association signal (lead SNP). † Genomic position in hg19. ‡ Unstandardized beta (Change in CMT = microns/allele; Change in BCVA = ETDRS letters/allele).

2.2.2. Suggestive Loci

We also identified several other loci with \(p\) values that were suggestive of association, but that did not reach genome-wide significance (\(\leq 5 \times 10^{-7}\)). Supplementary Materials: SNP.xlsx (sheet 1–2) summarizes the lead SNPs found in each of these suggestive loci with details of SNPs in LD. There were two suggestive loci for change in CMT: chromosome 4, Eph Receptor A5 (EPHA5) gene, lead SNP rs139041797, and chromosome 16, Deoxyribonuclease I (DNASE1) gene, lead SNP rs35275535. For change in BCVA, there were five suggestive loci: chromosome 11, Apolipoprotein O 3733.1 (APOO3733.1) gene, lead SNP rs78772036; chromosome 11, RP11-179A16.1 gene, lead SNP rs75537672 and four other individuals SNPs (rs17786210, rs76805698, rs77694097, rs117434848).
2.2.3. Conditional Analysis

Conditional analyses were applied to identify secondary association signals across the entire genome. For the change in CMT, analysis was performed conditioned on the lead SNPs, rs78466540, and rs11614480. For the change in BCVA, analysis was performed conditioned on the lead SNPs rs148980760, rs187876551, rs57801753, and rs118074968. No additional SNPs reached genome-wide or suggestive significance thresholds for either of the outcomes. The resulting Manhattan and Q–Q plots for the conditional analyses are presented in Supplementary Materials: Supplement: Figures S6 and S7.

2.2.4. Logistic Regression Model

A logistic regression model (responders vs. non-responders) was implemented stratifying outcomes on the basis of the functional and anatomical response. The baseline and clinical characteristics of responders and non-responders for both outcomes are shown in Supplementary Materials: Supplement: Table S2. Adjustments for relevant covariates were done based on the baseline clinical characteristics for each outcome. No variants reached genome-wide or suggestive significance thresholds for either the functional or anatomical outcome (Supplementary Materials: Supplement: Figures S8–S11).

3. Functional Annotation

Genome-Wide Significant Loci

The results of functional annotation for the genome-wide significant loci are given in Table 3. For the change in CMT, the lead SNP, rs11614480 had a Combined Annotation-Dependent Depletion (CADD) score of 18. Expression quantitative trait locus (eQTL) analysis showed that this SNP was associated with RP11-116D17.3 gene expression in several tissues in the Genotype-Tissue Expression (GTEx) database (Table 3). Furthermore, eQTL analysis showed a significant association between the RP11-116D17.3 gene and five nearby SNPs in LD with the lead SNP (rs721107, rs11610611, rs11610643, rs11611628, rs11609330) corresponding to multiple tissues including the pancreas and thyroid [Supplementary Materials: SNP.xlsv (Sheet 1 and 3)]. Of these, rs11610611 had a CADD score of 14.36 and rs11611628 a RegulomeDB score of 2a. For the change in BCVA, only rs118074968 and nearby SNPs in LD exhibited an eQTL effect for the Gap Junction Protein Alpha 1 (GJA1) gene in a single tissue [Table 3 and Supplementary Materials: SNP.xlsv (Sheet 2 and 3)].

### Table 3. Functional annotation of the lead SNPs at significantly associated loci.

| Locus * | Chr | Position † | Lead SNP | CADD Score | RegulomeDB Score (v1.1) | eQTL (GTEx v8) | Tissue | eGENE ‡ | eQTL (EyeGEx) | eGENE || Change in CMT (microns) |
|---------|-----|------------|----------|------------|--------------------------|----------------|--------|--------|-------------|--------|----------------|
| RP11-116D17.1 | 12 | 115772072 | rs11614480 | 18.42 | TRUE | Multiple tissues # | RP11-116D17.3 | FALSE | NA | NA | Change in CMT (microns) |
| CASC15 | 6 | 21755718 | rs78466540 | 1.37 | 7 | FALSE | NA | NA | FALSE | NA |

| Locus * | Chr | Position † | Lead SNP | CADD Score | RegulomeDB Score (v1.1) | eQTL (GTEx v8) | Tissue | eGENE ‡ | eQTL (EyeGEx) | eGENE |
|---------|-----|------------|----------|------------|--------------------------|----------------|--------|--------|-------------|--------|----------------|
| NTM | 11 | 132228056 | rs148980760 | 2.39 | 4 | FALSE | NA | NA | FALSE | NA | Change in BCVA (ETDRS letters) |
| RP11-744N12.3 | 11 | 128524088 | rs57801753 | 3.91 | 4 | FALSE | NA | NA | FALSE | NA |
| PGAM1P1 | 5 | 57535905 | rs187876551 | 0.40 | 4 | FALSE | NA | NA | FALSE | NA |
Significant gene expression corresponding to EyeGEx database.

Table 3. Functional annotation of the lead SNPs at significantly associated loci.

| Locus *  | Chr | Position † | Lead SNP  | CADD Score | RegulomeDB (v1.1) eQTL (GTEx v8) | Tissue | eGENE ‡ | eQTL (EyeGEx) eGENE ‡ |
|----------|-----|------------|-----------|------------|---------------------------------|--------|---------|---------------------|
| TBC1D32  | 6   | 121280029  | rs118074968 | 7.59       | TRUE                            | Skin-Not SunExposed | GJA1    | FALSE NA            |

Abbreviations: BCVA = best-corrected visual acuity; CADD = Combined Annotation-Dependent Depletion; CASC15 = cancer susceptibility candidate 15; Chr = chromosome; CMT = central macular thickness; eQTL= expression quantitative trait locus; ETDRS = early treatment diabetic retinopathy study; GJA1 = Gap Junction Protein Alpha 1; NTM = Neurotrimin; PGAM1P1 = Phosphoglycerate Mutase 1 Pseudogene 1; SNP = single nucleotide polymorphism; TBC1D32 = TBC1 Domain Family Member 32; # Multiple tissues: Adipose-Visceral, Adrenal gland, Spleen, Muscle-Skeletal, Heart-Left Ventricle, Atrial Appendage. * Locus assigned to gene within or nearest to the association signal (lead SNP), † Genomic positions are based on hg19. ‡ Significant gene expression corresponding to GTEx database. § Significant gene expression corresponding to EyeGEx database.

We also performed eQTL analysis for significant loci in retinal tissue using the Eye Genotype Expression (EyeGEx) database; however, no associations were observed between these variants and the expression of retinal genes [Table 3 and Supplementary Materials: SNP.xlsx (Sheet 1–3)].

4. Ocular Tissue Database

We queried the candidate genes for expression in different eye tissues and cells in the Ocular Tissue Database (OTDB), with results given in Supplementary Materials: Supplement: Table S3. A total of six genes were expressed in the OTDB. Of the six genes, the Probe Logarithmic Intensity Error score (PLIER score) was highest for the GJA1 gene (PLIER = 887.985) corresponding to choroid/retinal pigment epithelium. Regarding retinal tissue expression, the score was highest for the NTM gene (PLIER = 73.7647), followed by the GJA1 gene (PLIER = 61.0931).

5. Discussion

We identified multiple genome-wide significant loci associated with anti-VEGF response in DME, defined as either change in CMT or BCVA. After anti-VEGF injection, individuals carrying the alternate allele of rs78466540 (G) or rs11614480 (C) are more likely to be non-responders measured by the change in CMT. Likewise, those carrying the alternate allele of rs148980760 (C), rs187876551 (A), rs57801753 (C), or rs118074968 (G) are more likely to be non-responders measured by the change in ETDRS letters post-anti-VEGF injection. Two of the lead SNPs, rs11614480 and rs118074968, exhibited eQTL effects for the RP11-116D17.3 and GJA1 genes, respectively.

The locus corresponding to the CASC15 gene (chromosome 6; rs78466540) is associated with a sub-optimal reduction in CMT. CASC15 is a long intergenic non-coding RNA (lincRNA). This gene is involved in cellular programming, including proliferation, migration, and angiogenesis, in cancer cells via the hypoxia-induced VEGF pathway [20]. VEGF is a key player in the pathogenesis of diabetic retinal complications including DME [5] and is the molecular target of the anti-VEGF therapies under investigation here. However, as shown in the regional plot Supplementary Materials: Supplement: Figure S4A, this locus has very few supporting SNPs in LD and could be a false positive association. Consequently, the locus requires replication in additional datasets, as do all the findings reported here.

Another locus of interest is on chromosome 12 (lead SNP: rs11614480). This locus harbored several genome-wide significant SNPs, all in LD with the lead SNP, and is further supported by many SNPs showing suggestive associations with change in CMT. There is no definitive information available for the gene closest to this locus, RP11-116D17.1. This is a common finding for many GWAS [21,22], which often implicate gene deserts, genes of unknown function or with no HGNC symbol [23], or of previously unsuspected disease relevance. Most require replication in an independent population, and/or validation using other strategies, such as fine mapping and lab-based functional studies. It is also well known that the nearest gene to an association signal is not necessarily the causal gene [24].
Interestingly, this locus is a significant eQTL for \textit{RP11-116D17.3}, which is also near to the SNPs and is expressed in many biologically plausible tissues relevant to diabetes, including pancreas, adipose tissue, thyroid, pituitary, and adrenal gland. This locus is thus a plausible candidate for future studies.

Another noteworthy locus is on chromosome 11 (lead SNP: rs148980760). The closest gene to the lead SNP is \textit{NTM}, a member of the IgLON family that has been previously linked to late-onset Alzheimer’s disease, a neurodegenerative disorder \cite{25}. Interestingly, akin to disorders such as Alzheimer’s, the pathogenesis of DME is now considered part of a spectrum of a more comprehensive neurovascular and neurodegenerative process rather than a strictly vascular phenomenon \cite{26}.

Our eQTL analysis of significant loci also revealed some interesting genes: \textit{GJA1} and \textit{RP11-116D17.3}. The \textit{GJA1} gene, corresponding to eQTL rs118074968 (chr6), has been previously implicated in oculodentodigital syndrome \cite{27,28}. The \textit{RP11-116D17.3} gene has not been previously associated with disease, but as noted, this gene is expressed in several disease-relevant tissues. However, none of our significant loci were eQTLs for more retina-specific tissues in the EyeGEx database. Nonetheless, the \textit{GJA1} gene is highly expressed in the choroid, retinal pigment epithelium, and retinal tissue as observed in the OTDB (Supplementary Materials: Supplement: Table S3). The EyeGEx database does not differentiate distinct retinal layers or tissues, thus a lack of an association does not necessarily mean that there are no eQTLs. Although the EyeGEx database contains data from a substantial number of donors, a more comprehensive eQTL database including distinct layers of the retina would add significant value to the interpretation of our findings.

Response to anti-VEGF injections is measured by changes in BCVA and/or CMT. Given the use of both measurements in clinical decision making, both were used as outcomes in this study. While we also categorized our response measures into a case-control design using several vision and macular thickness criteria, we did not find any significant or suggestive loci for these phenotypes. Previous studies have shown that stratifying continuous data into categories can lead to information bias and loss of statistical power \cite{29,30}, the latter of which is likely to have affected our study, particularly due to its small sample size.

The response to anti-VEGF injection is likely affected by many clinical, genetic, and environmental factors. Our analyses have adjusted for several relevant confounding clinical factors including age, HbA1c, duration of DR, injection type, and baseline BCVA or CMT. In clinical practice, poor compliance leading to inadequate injection frequency is another important cause of the poor response. The frequency of injections in our study (8 ± 3) was similar to previous RCTs for DME \cite{31,32} and slightly higher than in other real-world studies \cite{33,34}; therefore, it is unlikely that undertreatment was a confounding factor. Furthermore, as the genomic control inflation factor \(\lambda\) was 1.000, our analyses suitably controlled for population stratification and cryptic relatedness. We included both T1 and T2 diabetes patients under the hypothesis that response to treatment for ocular complications would be driven by different factors than those that cause the sub-types of diabetes; stratified analyses would require a larger cohort. The two main limitations of this study were the small sample size and the lack of a replication cohort. However, we believe this is the first GWAS to date looking at the response to anti-VEGF treatment for DME and is one of only a handful of studies that have investigated the genetic determinants or molecular responses to anti-VEGF injections in DME \cite{14–17}. These prior studies also had sample size limitations, were focused on candidate genes, or were evaluating gene expression responses to treatment. Although the sample size is a limitation, this study has the largest DME anti-VEGF treatment cohort for a genetic study to date. Importantly, strong genetic effects can be detected with small but phenotypically homogenous samples, as demonstrated in our homogenous group of OCT-diagnosed DME patients with visual impairment. Next, owing to a retrospective design, a more detailed data collection regarding OCT biomarkers was not possible. Finally, no single type of anti-VEGF drug was used consistently in this study. Many patients received two or three different anti-VEGF agents over the course of 12 months, reflecting real-world practice. It is likely that the patients were switched to a
different anti-VEGF injection because they were not responding to their current agent, as has been reported in similar studies \[35,36\].

6. Conclusions
In conclusion, this study has identified several putative genetic variants that predict anti-VEGF treatment response. Given the relatively small cohort size, these associations should be considered provisional and replicated in adequately powered independent studies. International multi-center collaborations, including different ethnicities, will further advance our understanding of the biological pathways underpinning the treatment response of DME patients. Such studies may enable the development of novel therapies and the prediction of who will benefit from specific treatment modalities as we move towards precision medicine for the treatment of DME.

7. Materials and Methods
7.1. Study Design and Participants
This was a retrospective multi-center study involving multiple eye clinics in the Australian states of South Australia and Tasmania. All participants were enrolled through the Tasmanian Ophthalmic Biobank Study (University of Tasmania) or the Genetic Risk Factors in Complications of Diabetes Study (Flinders University). The eligibility criteria included T1 and T2 DM patients \(\geq 18\) years who had received any intravitreal anti-VEGF injections (Aflibercept, Regeneron; Bevacizumab, Genentech; Ranibizumab, Novartis) between 2013 and 2020 for the treatment of DME. DME cases were defined as those with clinically diagnosed center-involving DME and confirmed by central macular thickness (CMT \(\geq 315\) microns) measured by optical coherence tomography (OCT). Eyes with cysts in the central 1000 microns or any intraretinal or subretinal fluid were included in this study, independent of the CMT parameter. Exclusion criteria were: (a) any vitreoretinal surgery, systemic anti-VEGF therapy, or intra-ocular steroid in the six months preceding the initiation of anti-VEGF injection, (b) insufficient visibility of the fundus for retinal diagnosis, (c) incomplete follow-up data, and (d) inability to give consent. The better responding eye was included as the study eye for patients receiving bilateral anti-VEGF injections.

7.2. Phenotyping
Twelve months of retrospective data were collected from each participant’s medical record. The data included clinical and demographic characteristics (Table 1). Treatment decisions, including choice of anti-VEGF drug, switching between agents, re-treatment criteria, and treatment interval, were at the discretion of the treating physician and varied between clinics and doctors. BCVA, CMT, drug used, and injection number were recorded at baseline and at each injection visit. For statistical analysis, Snellen BCVA was converted to ETDRS letter scores \[37\].

7.3. Outcome Measures
The primary outcome measures were the change in CMT and BCVA at 12 months after treatment onset. The change was defined as the baseline CMT or BCVA before treatment subtracted from the final CMT or BCVA after 12 months and was analyzed as a quantitative variable. The data were further categorized into functional and anatomical responder or non-responder groups for exploration of secondary outcomes. A functional responder was defined as (1) \(\geq 5\) ETDRS letters improvement from baseline \[32,38\] or (2) \(\geq 15\) ETDRS letters improvement from baseline \[39,40\]. An anatomical responder was defined as \(\geq 10\%\) reduction in CMT from the baseline \[38,41\]. We also assessed a separate model wherein a functional non-responder was defined as \(\geq 5\) ETDRS letters loss from baseline \[38\]. Each defined group was compared to the remainder of the cohort.
7.4. Genotyping and Quality Control

Genomic DNA was extracted from peripheral venous blood (Illustria-DNA-extraction kit, BACC3) and quantitated using the Qubit Fluorometer (Thermo Fisher Scientific). A total of 234 DNA samples were genotyped on one of three different versions of the Illumina Global Screening Array SNP genotyping platform: GSAMD-24v3-0-EA_A1, GSA-24v1-0_C1, or GSA-24v3-0-A1. Genotypes were called using Genome Studio (version 2.0, Illumina, United States). QC of genotype data was performed using the Genome Studio genotyping module as described in Gua et al. [42]. Briefly, for each version of the array, poor quality markers (genotyping failed in >1% of samples) and poor quality DNA samples (genotyping failed for >1% of the markers) were removed. Additional QC procedures were undertaken as described in the Illumina genotyping technote, https://www.illumina.com/Documents/products/technotes/technote_infinium_genotyping_data_analysis.pdf (accessed on 18 October 2020); filtering of haploid markers: sex chromosome, mitochondrial, pseudo-autosomal; filtering of autosomal markers: cluster separation, AB R Mean, AB T Mean, Het Excess, Minor_Freq. The data from each array platform were then imported separately into PLINK (version 1.9/2.0) [43] where further QC was performed on each dataset separately and then again once the three datasets were merged (Supplementary Materials: Supplement: Table S1). Briefly, individuals with discordant sex information, a missing genotype rate >0.02, or heterozygosity ±6 SDs from the mean were excluded. Genetically related individuals were detected by calculating pairwise identity-by-descent/king-cut off, and the individual with the lower genotyping rate in any pair (identity-by-descent greater ≥ 0.2/king-cut off ≥ 0.0884) was removed. SNPs were excluded if they had a missing genotype rate >0.02 and/or had a minor allele frequency (MAF) <0.01.

Ancestral outliers were then identified using principal component analysis (PCA) based on pruned sets of autosomal SNPs from the merged datasets, selected by an LD r² threshold of 0.2 in windows of 50 SNPs and a moving step of five SNPs. By anchoring against 1000 Genomes (1KG), samples of European (EUR), Asian (ASN), Admixed American (AMR), and African (AFR) descent were identified. For our analyses, only individuals of European descent were included and individuals from other ethnicities and extreme outliers were excluded (Supplementary Materials: Supplement: Figure S1). Following QC, the merged GWAS dataset consisted of 221 individuals with genotyping data for 281,952 SNPs that were common to all three versions of the array.

7.5. Imputation

Imputation was performed using the Michigan imputation server [Minimac4 (1.5.7); https://imputationserver.sph.umich.edu/index.html#run/minimac4] (accessed on 12 January 2021). Using the Haplotype Reference Consortium panel (HRC panel, Version r1.1 2016), the allele dosage for over two million SNPs (after QC) was imputed for the 22 autosomal chromosomes. Post imputation, SNPs were excluded according to the following parameters: imputation quality score R² < 0.8, MAF < 0.02, missing genotype rate > 0.03, heterozygosity ±6 SDs from the mean, and HWE deviation p < 1 × 10⁻⁶ (Supplementary Materials: Supplement: Table S1). This resulted in a final GWAS dataset of 220 individuals with genotyped and imputed data for 2,581,674 autosomal SNPs.

7.6. GWAS Statistical Analysis

Associations between SNP genotypes (including imputed genotypes) and DME outcomes (change in CMT/BCVA) were evaluated by linear regression for continuous traits and logistic regression for categorical (responder/non-responder) groupings using PLINK2.0. Evidence for association was assessed using an additive model for risk by allele dose. The resulting residuals for change in CMT/BCVA distributions were approximately normally distributed. The original scales were used when reporting effect sizes (microns/allele for change in CMT and ETDRS letters/allele for change in BCVA). Age, HbA1c, duration of diabetic retinopathy (DR), injection type, and baseline CMT/BCVA were included in the model as covariates as they are consistently described in previous clin-
ical studies as influencing change in CMT or BCVA following anti-VEGF treatment [10,12]. The first three principal components (PCs) were also included as covariates to adjust for population stratification (Supplementary Materials: Figure S2). Genomic inflation factors (λ) were calculated to evaluate any residual population stratification in PLINK2.0. Q–Q plots and Manhattan plots were created in R version 4.0.2 (https://www.R-project.org/) with the GWASTools (Bioconductor: http://www.bioconductor.org) [44] and qqman package [45], respectively. Evidence for association was set at $p \leq 5 \times 10^{-8}$ for genome-wide significance and at $p \leq 5 \times 10^{-7}$ for suggestive significance. Local/regional association plots were constructed with FUMA v1.3.6 online tool (https://fuma.ctglab.nl/) (accessed on 18 January 2021) [46]. A locus was defined as 1Mb surrounding the genome-wide significant SNP, including any SNPs in LD ($r^2 \geq 0.4$) and the gene nearest to the lead SNP. We also performed conditional analysis to determine independent association signals across the entire genome, conditioning on the genome-wide significant SNPs.

Additionally, associations between SNP genotypes and secondary outcomes (functional or anatomical response) were evaluated using logistic regression, adjusting for covariates (age, duration of DR, HbA1c, baseline CMT/BCVA, and the first three PCs).

7.7. Demographic Data Statistical Analysis

For the demographic data, the mean change in BCVA and CMT from baseline to 12 months visits were conducted using paired Student t-tests in R version 4.0.2. $p < 0.05$ was considered statistically significant. Results are presented as the mean ± SD for continuous variables and as proportions (%) for categorical variables.

7.8. Functional Annotation

To discern key genes and variants at the identified GWAS loci, we conducted functional follow-up analyses through the FUMAgwas online portal. The following criteria incorporated in the annotation tool were applied: (1) CADD score (range 1–99) to determine the deleteriousness of the variant [47], (2) RegulomeDB score (range 1–7), for potential regulatory functions [48], and (3) eQTL analysis was performed using expression summary statistics from the GTEx database v8: http://www.gtexportal.org/home/datasets) (accessed on 18 January 2021) with a false discovery rate (FDR) < 0.05. As the GTEx database does not include ocular tissues, expression summary statistics for the candidate genes in the retina from the EyeGEx database (https://gtexportal.org/home/datasets > External datasets) (accessed on 18 January 2021) were used to evaluate whether any of our variants showed significant effects on expression levels at FDR < 0.05 [49]. Finally, we also queried our lead candidate genes from our association and eQTL analyses for expression in different ocular tissues, including the retina, using the ocular tissue database (https://genome.uiowa.edu/otdb/) (accessed on 20 January 2021) [50].

Supplementary Materials: The following supporting information can be downloaded at :https://www.mdpi.com/article/10.3390/ijms23074042/s1.

Author Contributions: Conceptualization: R.L.G., J.E.C. and K.P.B.; Data curation: R.L.G., E.L., G.K. and B.R.; Formal analysis: R.L.G.; Funding acquisition: K.P.B., B.J.M., J.E.C. and A.W.H.; Investigation: R.L.G.; Methodology: R.L.G., K.P.B., L.M.F., B.J.M., J.E.C. and N.V.; Project administration: R.L.G. and K.P.B.; Resources: L.M.F., E.L., G.K., B.R., A.W.H., B.J.V., N.V., J.E.C. and K.P.B.; Software: R.L.G.; Supervision: L.M.F., B.J.M., N.V. and K.P.B.; Writing—Original draft: R.L.G.; Writing—Review & editing: R.L.G., L.M.F., E.L., B.J.M., G.K., B.R., A.W.H., B.J.V., N.V., J.E.C. and K.P.B. All authors have read and agreed to the published version of the manuscript.

Funding: The study was funded by the Tasmanian Community Fund, the National Health and Medical Research Council (NHMRC) Australia Centre for Research Excellence (GNT1116360) and the Royal Hobart Hospital Research Foundation. RLG is supported by a scholarship from Diabetes Tasmania and the Patricia F Gordon Postgraduate Top-Up Scholarship in Medical Research. LMG is supported by the Gerald Harvey Senior Research Fellowship, University of Tasmania, and the
References

1. Lee, R.; Wong, T.Y.; Sabanayagam, C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015, 2, 1–25. [CrossRef] [PubMed]

2. Bhatwadekar, A.; Shughoury, A.; Belamkar, A.; Ciulla, T. Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World. Genes 2021, 12, 1200. [CrossRef] [PubMed]

3. Arar, N.H.; Freedman, B.I.; Adler, S.G.; Iyengar, S.; Chew, E.Y.; Davis, M.D.; Satko, S.G.; Bowden, D.W.; Duggirala, R.; Elston, R.C.; et al. Heritability of the Severity of Diabetic Retinopathy: The FIND-Eye Study. Invest. Ophthalmol. Vis. Sci. 2008, 49, 3839–3845. [CrossRef] [PubMed]

4. Zhang, X.; Zeng, H.; Bao, S.; Wang, N.; Gillies, M.C. Diabetic macular edema: New concepts in patho-physiology and treatment. Cell Biosci. 2014, 4, 27. [CrossRef] [PubMed]

5. Kent, D.; Vinores, S.A.; Campochiaro, P.A. Macular oedema: The role of soluble mediators. Br. J. Pathol. 2000, 84, 542–545. [CrossRef]

6. Kim, L.; D’Amore, P.A. A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis. Am. J. Pathol. 2012, 181, 376–379. [CrossRef]

7. Ciulla, T.A.; Pollack, J.S.; Williams, D.F. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: A real-world analysis of 28 658 patient eyes. Br. J. Ophthalmol. 2020, 105, 216–221. [CrossRef]

8. Cai, S.; Bressler, N.M. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: Recent clinically relevant findings. JAMA Ophthalmol. 2015, 133, 2504–2513.e1. [CrossRef]

9. Boyer, D.S.; Nguyen, Q.D.; Brown, D.M.; Basu, K.; Ehrlich, J.S.; Ride and Rise Research Group. Outcomes with as-needed ranibizumab after initial monthly therapy: Long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology 2015, 122, 2504–2513.e1. [CrossRef]

10. Brown, D.M.; Nguyen, Q.D.; Marcus, D.M.; Boyer, D.S.; Patel, S.; Feiner, L.; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RIDE and RIDE. Ophthalmology 2013, 120, 2013–2022. [CrossRef]

11. Pelosini, L.; Hull, C.C.; Boyce, J.F.; McHugh, D.; Stanford, M.R.; Marshall, J. Optical Coherence Tomography May Be Used to Predict Visual Acuity in Patients with Macular Edema. Investig. Ophthalmology Vis. Sci. 2011, 52, 2741–2748. [CrossRef] [PubMed]

12. Bressler, S.B.; Ozda, I.; Maguire, M.G.; Dhoot, D.S.; Glassman, A.R.; Jampol, L.M.; Diabetic Retinopathy Clinical Research Network. Factors Associated with Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti–Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol. 2019, 137, 382–389. [CrossRef] [PubMed]

13. Sophie, R.; Lu, N.; Campochiaro, P.A. Predictors of Functional and Anatomical Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab. Ophthalmology 2015, 122, 1395–1401. [CrossRef]

14. Toraih, E.A.; Abd Elghany, A.A.; Abd El Fadeel, N.M.; Al Ageeli, E.; Fawzy, M.S. Deciphering the role of circulating lncRNAs: RNCR2, NEAT2, CDKN2B-AS1, and PVT1 and the possible prediction of anti-VEGF treatment outcomes in diabetic retinopathy patients. Graefes Arch. Clin. Exp. Ophthalmol. 2019, 257, 1897–1913. [CrossRef]

15. Tetikoglu, M.; Yuksel, Z.; Aktas, S.; Sagdic, H.M.; Ozcura, F. VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema. Int. Ophthalmol. 2017, 38, 2381–2388. [CrossRef] [PubMed]
39. Boyer, D.S.; Hopkins, J.J.; Sorof, J.; Ehrlich, J.S. Anti-vascular endothelial growth factor therapy for diabetic macular edema. *Ther. Adv. Endocrinol. Metab.* 2013, 4, 151–169. [CrossRef]

40. Holekamp, N.M.; Campbell, J.; Almony, A.; Ingraham, H.; Marks, S.; Chandwani, H.; Cole, A.L.; Kiss, S. Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. *Am. J. Ophthalmol.* 2018, 191, 83–91. [CrossRef]

41. Ashraf, M.; Souka, A.; Adelman, R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: A review of the literature. *Br. J. Ophthalmol.* 2016, 100, 1596–1604. [CrossRef] [PubMed]

42. Guo, Y.; He, J.; Zhao, S.; Wu, H.; Zhong, X.; Sheng, Q.; Samuels, D.; Shyr, Y.; Long, J. Illumina human exome genotyping array clustering and quality control. *Nat. Protoc.* 2014, 9, 2643–2662. [CrossRef] [PubMed]

43. Chang, C.C.; Chow, C.C.; Tellier, L.C.; Vattikuti, S.; Purcell, S.M.; Lee, J. Second-generation PLINK: Rising to the challenge of larger and richer datasets. *GigaScience* 2015, 4, 7. [CrossRef] [PubMed]

44. Gogarten, S.M.; Bhangale, T.; Conomos, M.P.; Laurie, C.A.; McHugh, C.P.; Painter, I.; Zheng, X.; Crosslin, D.R.; Levine, D.; Lumley, T.; et al. GWASTools: An R/Bioconductor package for quality control and analysis of genome-wide association studies. *Bioinformatics* 2012, 28, 3329–3331. [CrossRef] [PubMed]

45. Turner, S.D. qzman: An R package for visualizing GWAS results using Q-Q and manhattan plots. *Biorxiv* 2014. Biorxiv:005165.

46. Watanabe, K.; Taskesen, E.; van Bochoven, A.; Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* 2017, 8, 1–11. [CrossRef]

47. Kircher, M.; Witten, D.M.; Jain, P.; O’roak, B.J.; Cooper, G.M.; Shendure, J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet.* 2014, 46, 310–315. [CrossRef]

48. Boyle, A.P.; Hong, E.L.; Hariharan, M.; Cheng, Y.; Schaub, M.A.; Kasowski, M.; Karczewski, K.J.; Park, J.; Hitz, B.C.; Weng, S.; et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* 2012, 22, 1790–1797. [CrossRef]

49. Ratnapriya, R.; Sosina, O.A.; Starostik, M.R.; Kwicklis, M.; Kapphahn, R.J.; Fritsche, L.G. Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration. *Nat. Genet.* 2019, 51, 606–610. [CrossRef]

50. Wagner, A.; Anand, V.N.; Wang, W.-H.; Chatterton, J.E.; Sun, D.; Shepard, A.R.; Jacobson, N.; Pang, I.-H.; DeLuca, A.; Casavant, T.L.; et al. Exon-level expression profiling of ocular tissues. *Exp. Eye Res.* 2013, 111, 105–111. [CrossRef]